Research in the Annals of the Rheumatic Diseases found no difference in efficacy, safety or immunogenicity when switching from Humira, or adalimumab, to the FDA-approved biosimilar Cyltezo, from Boehringer Ingelheim.
Switch to biosimilar referencing Humira is safe and effective, study shows
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.